[Asia Economy Reporter Hyunseok Yoo] Boditech Med is showing strong performance. It appears that the news of receiving export approval for kits capable of diagnosing mutated COVID-19 viruses has had an impact.
As of 2:07 PM on the 23rd, Boditech Med was trading at 24,300 KRW, up 9.21% (2,050 KRW) compared to the previous trading day.
On the same day, Boditech Med announced that it had obtained export approval from the Ministry of Food and Drug Safety for two types of multiplex PCR kits capable of simultaneously diagnosing three specific genes of COVID-19 (ExAmplex COVID-19 PCR 3-gene kit, ExAmplex COVID-19 PCR 3-gene Lyo kit).
The approved PCR kits were developed through collaboration between Boditech Med and its molecular diagnostics subsidiary, EugeneCell. By detecting three characteristic genes of COVID-19 simultaneously from a single specimen collection, the kits can accurately determine infection status. Additionally, both liquid formulations suitable for high-volume testing environments and lyophilized formulations that can be used in testing environments lacking facilities such as freezers are provided, allowing the kits to meet diverse market demands.
In particular, the company explained that these products can accurately diagnose COVID-19 regardless of mutations, including existing variants from the UK, South Africa, Brazil, as well as the rapidly spreading Indian variant.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
